How to buy Osmotica Pharmaceuticals stock

Osmotica Pharmaceuticals plc is a biotechnology business based in the US. Osmotica Pharmaceuticals shares (OSMT) are listed on the NASDAQ and all prices are listed in US Dollars. Osmotica Pharmaceuticals employs 379 staff and has a trailing 12-month revenue of around 0.00.

Osmotica Pharmaceuticals share price

Use our graph to track the performance of OSMT stocks over time.

Osmotica Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-03-10.

52-week range	$2.81 - $7.38
50-day moving average	$4.24
200-day moving average	$5.20
Wall St. target price	$8.40
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-4.82

Buy Osmotica Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Osmotica Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Osmotica Pharmaceuticals plc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Osmotica Pharmaceuticals under- or over-valued?

Valuing Osmotica Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Osmotica Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Osmotica Pharmaceuticals's EBITDA

Osmotica Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $32.7 million.

The EBITDA is a measure of a Osmotica Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Osmotica Pharmaceuticals financials

Revenue TTM	$203.3 million
Operating margin TTM	8.37%
Gross profit TTM	$128.4 million
Return on assets TTM	2.31%
Return on equity TTM	-35.13%
Profit margin	-25.27%
Book value	$2.39
Market capitalisation	$230.3 million

TTM: trailing 12 months

Shorting Osmotica Pharmaceuticals shares

There are currently 1.8 million Osmotica Pharmaceuticals shares held short by investors – that's known as Osmotica Pharmaceuticals's "short interest". This figure is 8.8% down from 2.0 million last month.

There are a few different ways that this level of interest in shorting Osmotica Pharmaceuticals shares can be evaluated.

Osmotica Pharmaceuticals's "short interest ratio" (SIR)

Osmotica Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Osmotica Pharmaceuticals shares currently shorted divided by the average quantity of Osmotica Pharmaceuticals shares traded daily (recently around 343386.05947955). Osmotica Pharmaceuticals's SIR currently stands at 5.38. In other words for every 100,000 Osmotica Pharmaceuticals shares traded daily on the market, roughly 5380 shares are currently held short.

However Osmotica Pharmaceuticals's short interest can also be evaluated against the total number of Osmotica Pharmaceuticals shares, or, against the total number of tradable Osmotica Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Osmotica Pharmaceuticals's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Osmotica Pharmaceuticals shares in existence, roughly 30 shares are currently held short) or 0.1306% of the tradable shares (for every 100,000 tradable Osmotica Pharmaceuticals shares, roughly 131 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Osmotica Pharmaceuticals.

Find out more about how you can short Osmotica Pharmaceuticals stock.

Osmotica Pharmaceuticals share dividends

We're not expecting Osmotica Pharmaceuticals to pay a dividend over the next 12 months.

Osmotica Pharmaceuticals share price volatility

Over the last 12 months, Osmotica Pharmaceuticals's shares have ranged in value from as little as $2.81 up to $7.38. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Osmotica Pharmaceuticals's is 2.3771. This would suggest that Osmotica Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Osmotica Pharmaceuticals overview

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone, a chlorzoxazone scored tablet for muscle spasms; ConZip, a tramadol hydrochloride extended-release capsule to treat pain; and Arbaclofen tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity. It also provides women's health products, including Divigel for menopause, as well as OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods; and RVL-1201, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis. In addition, the company's non-promoted products comprise methylphenidate ER tablets for ADHD; venlafaxine ER tablets to treat major depressive disorder and social anxiety disorder; hydromorphone ER for treating pain; nifedipine ER for hypertension; sodium benzoate/sodium phenylacetate for the treatment of hyperammonemia; oxybutynin ER for overactive bladder; and prescription prenatal vitamins for treating nutritional requirements during pregnancy, as well as Osmodex and other abbreviated new drug applications. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey. .

Frequently asked questions

What percentage of Osmotica Pharmaceuticals is owned by insiders or institutions?
Currently 49.638% of Osmotica Pharmaceuticals shares are held by insiders and 42.282% by institutions. How many people work for Osmotica Pharmaceuticals?
Latest data suggests 379 work at Osmotica Pharmaceuticals. When does the fiscal year end for Osmotica Pharmaceuticals?
Osmotica Pharmaceuticals's fiscal year ends in December. Where is Osmotica Pharmaceuticals based?
Osmotica Pharmaceuticals's address is: 400 Crossing Boulevard, Bridgewater, NJ, United States, 08807 What is Osmotica Pharmaceuticals's ISIN number?
Osmotica Pharmaceuticals's international securities identification number is: IE00BF2HDL56 What is Osmotica Pharmaceuticals's CUSIP number?
Osmotica Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: G6S41R101